Compare Abbott Laboratories (ABT) vs Macy's Inc (M) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Macy's Inc — how do they compare? Abbott Laboratories trades at $95.58 (market cap $166.94B), while Macy's Inc trades at $22.45 (market cap $6.08B). The key difference: Abbott Laboratories is far larger — about 27.5× Macy's Inc's market cap, and Macy's Inc pays the higher dividend (3.31%). Which is the better fit depends on your goals.
| ABT | M | |
|---|---|---|
Market Cap | $166.94B | $6.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $25.96 |
52-Week Low | $82.57 | $11.90 |
Enterprise Value | $193.69B | $9.90B |
Dividend Yield | 2.63% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Macy's (M) trades at $23.13, down 0.52% on the day, with technical indicators showing a bullish trend supported by moving averages. The stock shows attractive valuation metrics with a P/E of 9.79 and P/S of 0.29, while recent earnings have consistently beaten expectations. The company's 'Bold New Chapter' strategy is gaining traction with improved comparable sales and digital growth, supported by Berkshire Hathaway's new 3.04 million-share position disclosed in Q1 2026.
Macy's presents a compelling value opportunity with strong institutional interest and operational improvements, though investors face risks from retail sector headwinds and margin pressure. The consensus price target of $23.80 suggests modest upside potential, while execution on turnaround initiatives remains critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
